GFAP-C6
A fragment of glial fibrillary acidic protein cleaved by caspase-6, enabling non-invasive monitoring of astrocytic activation and central nervous system injury.
Key features and values
- Quantifies caspase-6-generated GFAP fragments indicative of astrocytic activation.
- Reflects central nervous system injury and associated pathological processes.
- Provides a non-invasive measure of astrocytic response to neurological damage.
- Supports monitoring of disease progression and response to therapies targeting neurodegeneration.
- Applicable in research on conditions such as traumatic brain injury and neurodegenerative diseases.
- Facilitates evaluation of interventions aimed at modulating astrocytic activation and CNS injury.
- Complements other biomarkers for a comprehensive assessment of neuroinflammatory and neurodegenerative processes.
Description
The GFAP-C6 biomarker assay measures specific fragments of glial fibrillary acidic protein resulting from caspase-6-mediated cleavage, serving as an indicator of astrocytic activation and central nervous system injury. This non-invasive assay provides insights into astrocytic responses associated with neurological damage and neurodegenerative processes. By quantifying GFAP degradation products, the GFAP-C6 assay aids in monitoring disease progression, evaluating treatment efficacy, and understanding the underlying mechanisms of CNS injury and astrocytic activation. It serves as a valuable tool in research settings for assessing the dynamics of neuroinflammation and neurodegeneration.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
